Healthcare Services

Chemotherapy-Induced Neutropenia Treatment Market Outlook 2026–2035 Driven by Key Growth Factors and Industry Projections

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Chemotherapy-Induced Neutropenia Treatment Market During The Forecast Period 2026–2030?

The chemotherapy-induced neutropenia treatment market size has experienced significant growth in recent years. It is projected to expand from $0.62 billion in 2025 to $0.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical expansion is attributable to factors such as the increasing incidence of chemotherapy-induced neutropenia, the expansion of aggressive cancer treatment protocols, the availability of colony-stimulating factors, improved clinical monitoring practices, and the growth of oncology treatment facilities.

The chemotherapy-induced neutropenia treatment market size is anticipated to experience substantial expansion over the coming years. This market is projected to reach $0.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. The anticipated increase during this period stems from factors such as the greater acceptance of long-acting growth factors, a heightened emphasis on managing neutropenia in outpatient settings, wider use of biosimilar G-CSF, increased investments in strategies to prevent infections, and breakthroughs in immunomodulatory treatments. Key developments expected during the forecast period involve a greater uptake of prophylactic G-CSF therapy, an increased reliance on early intervention treatment approaches, a stronger focus on reducing infection risks, the broadening of personalized neutropenia management, and improved monitoring of white blood cell counts.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp

Which Economic Or Industry Drivers Are Impacting The Chemotherapy-Induced Neutropenia Treatment Market?

The rising number of cancer cases is anticipated to drive expansion in the chemotherapy-induced neutropenia treatment market going forward. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the body. This increase in cancer diagnoses stems from an aging demographic, given that older people face an elevated likelihood of developing the disease owing to accumulated genetic changes and diminished immune capabilities across their lifespan. Chemotherapy-induced neutropenia treatment supports cancer management by lowering the chances of infection via immune system bolster, allowing patients to undergo chemotherapy courses with fewer interruptions. Such treatment improves results by reducing adverse events, consequently boosting overall patient safety and their standard of living. To illustrate, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 new cases daily, with males accounting for roughly 55% of these reported cases. Consequently, the growing occurrence of cancer is a key factor propelling the expansion of the chemotherapy-induced neutropenia treatment market.

What Market Segments Are Evaluated Within The Chemotherapy-Induced Neutropenia Treatment Market?

The chemotherapy-induced neutropenia treatment market covered in this report is segmented –

1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types

2) By Route of Administration: Subcutaneous, Intravenous

3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics

2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim

3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion

4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy

What Trends Are Affecting The Expansion Of The Chemotherapy-Induced Neutropenia Treatment Market?

Leading companies within the chemotherapy-induced neutropenia treatment market are prioritizing the creation and regulatory clearance of advanced products, particularly long-acting formulations. These formulations aim to enhance patient ease, decrease how often doses are administered, and boost adherence to treatment regimens. Long-acting formulations are drug preparations specifically designed to release their active components gradually over an extended timeframe, thereby minimizing the need for frequent dosing. For example, in December 2023, the U.S. Food and Drug Administration (FDA) granted approval to Coherus BioSciences Inc., a US-based biopharmaceutical company, for Udenyca Onbody. This innovative, pre-filled on-body injector uses a long-acting formulation to automatically administer pegfilgrastim around 27 hours following chemotherapy, removing the requirement for an injection on the subsequent day. Udenyca Onbody significantly improves the patient journey by guaranteeing prompt prophylactic care for chemotherapy-induced neutropenia, while simultaneously cutting down on clinic visits and improving compliance.

Who Are The Top Market Participants Influencing The Chemotherapy-Induced Neutropenia Treatment Market?

Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation

Read the full chemotherapy-induced neutropenia treatment market report here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-neutropenia-treatment-global-market-report

What Are The Top-Performing Regions Within The Chemotherapy-Induced Neutropenia Treatment Market?

North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chemotherapy-Induced Neutropenia Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp

Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2026, By The Business Research Company

Chemotherapy Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Chemotherapy Induced Anemia Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795